Thomas B. Neff Sells 18,900 Shares of FibroGen, Inc (FGEN) Stock
FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,900 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $51.29, for a total transaction of $969,381.00. Following the transaction, the chief executive officer now owns 3,297,655 shares in the company, valued at approximately $169,136,724.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
FibroGen, Inc (NASDAQ:FGEN) traded up 0.58% during midday trading on Friday, reaching $52.40. 1,462,946 shares of the company’s stock traded hands. The firm’s 50-day moving average is $42.78 and its 200 day moving average is $31.87. The firm’s market cap is $3.73 billion. FibroGen, Inc has a 52-week low of $15.60 and a 52-week high of $52.70.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $29.00 million during the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Equities research analysts expect that FibroGen, Inc will post ($1.80) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/15/thomas-b-neff-sells-18900-shares-of-fibrogen-inc-fgen-stock-2.html.
Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of FibroGen by 15.1% during the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after purchasing an additional 761,421 shares during the last quarter. BlackRock Inc. raised its holdings in shares of FibroGen by 12.3% during the second quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock valued at $161,545,000 after purchasing an additional 546,587 shares during the last quarter. FMR LLC raised its holdings in shares of FibroGen by 96.9% during the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after purchasing an additional 1,641,423 shares during the last quarter. State Street Corp raised its holdings in shares of FibroGen by 16.4% during the second quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock valued at $56,962,000 after purchasing an additional 248,922 shares during the last quarter. Finally, Hillhouse Capital Management Ltd. raised its holdings in shares of FibroGen by 75.0% during the second quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $56,525,000 after purchasing an additional 750,000 shares during the last quarter. 47.49% of the stock is owned by institutional investors and hedge funds.
FGEN has been the topic of several research reports. Stifel Nicolaus reiterated a “buy” rating and set a $38.00 price objective (up previously from $32.00) on shares of FibroGen in a report on Thursday, June 22nd. BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. William Blair reiterated an “outperform” rating on shares of FibroGen in a report on Monday, June 26th. Citigroup Inc. reiterated a “buy” rating and set a $48.00 price objective on shares of FibroGen in a report on Monday, June 26th. Finally, Jefferies Group LLC initiated coverage on shares of FibroGen in a report on Monday, July 10th. They set a “buy” rating and a $50.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. FibroGen presently has an average rating of “Buy” and an average price target of $60.17.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.